Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Completed
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +117 locations
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Recruiting
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: London Health Sciences Centre, London, Ontario
Conditions: Obesity, Chronic Kidney Disease
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
Completed
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months)... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/16/2024
Locations: Velocity Clinical Research San Diego, La Mesa, California +64 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
Completed
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 different tablet versions. In addition to semaglutide, the tablet versions contain different helping agents in different amounts. Both tablet versions have a helping agent called SNAC. The main aim of this study is to investigate semaglutide of 4 different doses in a new tablet by determining the amount of semaglutide in the blood and compare the concentration in the blood for the new tablet with the tablet... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +1 locations
Conditions: Healthy Participants
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
Completed
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participants blood sugar levels. Participants will get Rybelsus® as prescribed to them by their study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor. P... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Master Centre for Canada, Mississauga, Ontario
Conditions: Diabetes Mellitus, Type 2
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
Completed
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screenin... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +2 locations
Conditions: Healthy Volunteers, Type 2 Diabetes
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
Active Not Recruiting
This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/12/2024
Locations: Toronto Western Hospital, Toronto, Ontario
Conditions: Major Depressive Disorder
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Completed
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/06/2024
Locations: Central Alabama Research, Birmingham, Alabama +832 locations
Conditions: Overweight, Obesity
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
Terminated
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Ry... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2024
Locations: Trinity Clinical Research, Centreville, Alabama +89 locations
Conditions: Diabetes Mellitus, Obesity
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
Completed
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation. Sem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +50 locations
Conditions: Obesity, Overweight
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Completed
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the p... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: American Clinical Trials, Buena Park, California +121 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
Completed
In this study, four new tablet versions of two compounds will be investigated. The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood after doses of four different tablet versions. The tablet versions, participants will receive, i.e. the treatment arm participants will be assigned to, is decided by chance. Participants will receive one treatment for 10 days in the first period. For the second period, directly following, participants will rece... Read More
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
05/27/2024
Locations: Altasciences Company Inc., Montreal, Quebec +1 locations
Conditions: Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes